Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 9086 results
Found 9086 results.

AIDS-Related Opportunistic Infections

Wood BR, Komarow L, Zolopa AR, Finkelman MA, Powderly WG, Sax PE. "Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms." AIDS. 2013;27(6):967-72.
Havlir DV, Kendall MA, Ive P, et al. "Timing of antiretroviral therapy for HIV-1 infection and tuberculosis." N. Engl. J. Med.. 2011;365(16):1482-91.
Valcour V, Yeh T-M, Bartt R, et al. "Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection." HIV Med.. 2009;10(2):103-10.
L Wheat J, Connolly P, Smedema M, et al. "Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole." J. Antimicrob. Chemother.. 2006;57(6):1235-9.
Geng EH, Kahn JS, Chang OC, et al. "The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation." Clin. Infect. Dis.. 2011;53(10):1008-14.
Périssé ARS, Smeaton L, Chen Y, et al. "Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease." PLoS ONE. 2013;8(12):e83643.
Tenforde MW, Gupte N, Dowdy DW, et al. "C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings." PLoS ONE. 2015;10(2):e0117424.
Wohl DA, Kendall MA, Andersen J, et al. "Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030." HIV Clin Trials. 2009;10(3):143-52.
Mugavero MJ, Pence BWells, Whetten K, et al. "Predictors of AIDS-related morbidity and mortality in a southern U.S. Cohort." AIDS Patient Care STDS. 2007;21(9):681-90.
Weinberg A, Tierney C, Kendall MA, et al. "Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy." J. Infect. Dis.. 2006;193(4):488-93.
Servoss JC, Kitch DW, Andersen JW, Reisler RB, Chung RT, Robbins GK. "Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999)." J. Acquir. Immune Defic. Syndr.. 2006;43(3):320-3.
Grant PM, Komarow L, Sanchez A, et al. "Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164." HIV Clin Trials. 2014;15(4):133-9.
Sax PE, Sloan CE, Schackman BR, et al. "Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164." HIV Clin Trials. 2010;11(5):248-59.
De Luca A, Ammassari A, Pezzotti P, et al. "Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis." AIDS. 2008;22(14):1759-67.
Hosseinipour MC, Bisson GP, Miyahara S, et al. "Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial." Lancet. 2016;387(10024):1198-209.

AIDS-Associated Nephropathy

Bruggeman LA, O'Toole JF, Ross MD, et al. "Plasma apolipoprotein L1 levels do not correlate with CKD." J. Am. Soc. Nephrol.. 2014;25(3):634-44.

AIDS Vaccines

J Kilby M, R Bucy P, Mildvan D, et al. "A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)." J. Infect. Dis.. 2006;194(12):1672-6.
Li JZ, Christensen JA, Wang H, Spritzler J, Kuritzkes DR. "Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption." J. Acquir. Immune Defic. Syndr.. 2012;61(1):19-22.
Li JZ, Heisey A, Ahmed H, et al. "Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study." AIDS. 2014;28(18):2649-57.
Schooley RT, Spritzler J, Wang H, et al. "AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein." J. Infect. Dis.. 2010;202(5):705-16.
Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. "What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials." J. Infect. Dis.. 2003;188(2):179-93.
Li JZ, Brumme CJ, Lederman MM, et al. "Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial." PLoS ONE. 2012;7(3):e34134.
Li JZ, Brumme ZL, Brumme CJ, et al. "Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial." J. Infect. Dis.. 2011;203(7):976-83.
Jacobson JM, Zheng L, Wilson CC, et al. "The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection." J. Acquir. Immune Defic. Syndr.. 2016;71(2):163-71.
Gandhi RT, O'Neill D, Bosch RJ, et al. "A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy." Vaccine. 2009;27(43):6088-94.
Yang Y, Degruttola V. "Resampling-based methods in single and multiple testing for equality of covariance/correlation matrices." Int J Biostat. 2012;8(1):Article 13.